MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $2.75 (60.82% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Wells FargoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016RBC CapitalReiterated RatingSector Perform$2.00 -> $1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015WallachBeth CapitalLower Price TargetBuy$6.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit SuisseInitiated CoverageUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.10)($0.09)$9.02 million$9.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.13)($0.13)$8.26 million$7.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.13)($0.11)$8.87 million$9.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.14)($0.11)$10.95 million$9.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.14)($0.10)$10.56 million$12.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.12)($0.15)$10.36 million$9.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.12)($0.05)$10.90 million$8.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2014Q2 14($0.11)$0.03$9.81 million$12.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.10)($0.12)$7.98 million$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.02($0.11)$7.00 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.12)($0.08)$5.30 million$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.15$0.18$57.30 million$68.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2013Q1 2013$0.11$0.09$50.36 million$2.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2013Q4 2012($0.03)($0.10)$21.94 million$1.94 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.11)($0.07)$3.72 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.08)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.14)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.15)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2011($0.21)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2011($0.22)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline
06/29/16 02:32 PMArena Pharmaceuticals, Inc. Stock Momentum Hits Weakness - CML News
06/28/16 07:51 AMCovering the Bases on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Where is the Stock Going? - Press Telegraph
06/28/16 07:12 AMArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June 28, 2016 -
06/27/16 07:19 AMAnalysts Update on Stocks: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , The Medicines Company (NASDAQ:MDCO) - Street Updates
06/26/16 02:30 PMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 02:34 PMArena Pharmaceuticals Incorporated (NASDAQ:ARNA) Shorts Decreased by 4.07% After Short Covering - Engelwood Daily
06/24/16 02:34 PMPrice Target Update on Arena Pharmaceuticals (NASDAQ:ARNA) - Trade Calls
06/23/16 10:23 AMEarnings Estimates Report: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - iStreetWire
06/22/16 07:44 PMArena Pharmaceuticals, Inc. Stock Momentum at Critical Inflection Point - CML News
06/22/16 02:34 PMArena Pharmaceuticals (NASDAQ:ARNA) Analyst Rating Consensus - TheFounders Daily
06/19/16 07:18 AMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 02:32 PMStocks within investor Spotlight: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , NuVasive, Inc. (NASDAQ:NUVA) - Street Updates
06/17/16 10:29 AMKevin Lind Appointed CFO of Arena Pharmaceuticals
06/16/16 02:34 PMNews Fact on Vanguard Level- Arena Pharmaceuticals (NASDAQ:ARNA), QLT Inc. (NASDAQ:QLTI), BioScrip ... - Seneca Globe
06/16/16 02:34 PMBlazing Stocks Calls Bulls- Arena Pharmaceuticals (NASDAQ:ARNA), Dynegy (NYSE:DYN), Novartis (NYSE:NVS) - Seneca Globe
06/16/16 05:07 AMARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh -
06/15/16 02:37 PMArena Pharmaceuticals Hires Kevin Lind As CFO - Benzinga
06/15/16 11:18 AMArena Pharmaceuticals Hires Kevin Lind As CFO - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) revealed Wednesday that Kevin Lind would join its management team as EVP and CFO effective June 15, 2016. According to the company, Lind would report to Amit Munshi, its President and CEO. Munshi commented, "Kevin is an accomplished executive with significant financial expertise and will be an exceptional addition to our team. Kevin's broad finance experience ...Full story available on Benzinga.com
06/15/16 06:19 AMArena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer - [at noodls] - SAN DIEGO, June 15, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind will join its management team as Executive Vice President and Chief Financial Officer, ...
06/15/16 06:01 AM7:01 am Arena Pharm announces Kevin Lind will join as CFO, effective June 15 -
06/14/16 02:34 PMYesterday Stock's Price Swings: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , PDL BioPharma, Inc. (NASDAQ:PDLI) - Street Updates
06/14/16 07:44 AMPrice Target Summary Report: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Seabridge Gold, Inc. (NYSE:SA) - Beacon Chronicle
06/13/16 03:41 PMARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure -
06/13/16 10:38 AMArena Pharma (ARNA) Announces USAN Approval of Adopted Name for APD334 - StreetInsider.com
06/13/16 10:38 AMHC Stocks Indications: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Inovio Pharmaceuticals Inc (NASDAQ:INO) - share market updates (press release)
06/13/16 06:09 AMArena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 - [at noodls] - SAN DIEGO, June 13, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced ...
06/10/16 11:01 AMCurrent Update on Price Fluctuations: Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) , Arena Pharmaceuticals, Inc ... - Street Updates
06/09/16 11:28 AMAnalysts Actions to Track: Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) , Arena Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/09/16 11:28 AMEarnings Estimates to see: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - News Oracle
06/09/16 11:28 AMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Fundamental Star Rating Report - CML News
06/08/16 08:56 PMArena Pharmaceuticals Inc. (ARNA) Jumps 9.69% on June 08 - Equities.com
06/08/16 11:01 AMTwo Stocks within Traders Limelight: Aetna Inc. (NYSE:AET) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates
06/07/16 08:08 PMArena Pharmaceuticals Inc. (ARNA) Jumps 7.49% on June 06 - Equities.com
06/07/16 02:36 PMRevenue Estimates Spotlight: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - News Oracle
06/06/16 07:47 PMEarnings in Focus: LinkedIn Corporation (NYSE:LNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Beacon Chronicle
06/06/16 07:47 PMARENA PHARMACEUTICALS INC. (NASDAQ:ARNA) Financial Condition Compared to S&P 500 - CML News
06/06/16 12:05 PMArena - Stock Climbs As Belviq Sales Falter - Seeking Alpha
06/06/16 12:05 PMThe Insider Activity Don't Lie: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - iStreetWire
06/05/16 10:29 AMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Broker Price Targets For The Coming Week - Share Trading News
06/04/16 11:03 AMArena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/03/16 08:39 PMEarnings Estimates Highlight: Newell Brands Inc. (NYSE:NWL), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Beacon Chronicle
06/03/16 02:39 PMSome Traders Are Very Bearish on Arena Pharmaceuticals, Inc. After Forming Bearish Multiple Bottom Pattern - HNN
06/03/16 02:39 PMHC Stocks Trading Summary: Edwards Lifesciences Corp (NYSE:EW), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - share market updates (press release)
06/03/16 11:02 AMPreview of Analysts Recommendation: Relypsa, Inc. (NASDAQ:RLYP) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates
06/02/16 08:34 PMArena Pharmaceuticals Inc. (ARNA) Jumps 7.82% on June 02 - Equities.com - Arena Pharmaceuticals Inc. (ARNA) Jumps 7.82% on June 02Equities.comArena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 7.82% to $1.93, representing a gain of $0.14 per share. Some 2.83 million shares traded hands on 5,948 trades, compared ...and more »
06/01/16 11:01 AMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - share market updatesArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 ...Analyst Watch List Stocks: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)WsNews 4investorsall 14 news articles »
06/01/16 11:01 AMWhat should one expect from? - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), TEGNA Inc. (NYSE:TGNA) - Beacon Chronicle - Beacon ChronicleWhat should one expect from? - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), TEGNA Inc. (NYSE:TGNA)Beacon ChronicleLast Trade: The Company closed its last session at $22.96 with the gain of 0.75%. The market capitalization of the company is $5.03 Billion, with the average Volume of 1.7 Million. The stock currently has its 52-Week High range of $38.48 and 52-week ...and more »
06/01/16 09:51 AMArena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? -
06/01/16 09:46 AMThe Little-Known Reason Arena Pharmaceuticals Could Be a Winner - Hint: It’s not obesity drug Belviq! Find out where investors should focus their attention instead.
05/31/16 08:17 PMArena Pharmaceuticals Inc. (ARNA) Jumps 8.02% on May 30 - Equities.com - Arena Pharmaceuticals Inc. (ARNA) Jumps 8.02% on May 30Equities.comArena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 8.02% to $1.75, representing a gain of $0.13 per share. Some 2.39 million shares traded hands on 4,850 trades, compared with ...and more »
About Arena Pharmaceuticals

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company's drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserin's once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Company's other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARNA
  • CUSIP: 04004710
Key Metrics:
  • Previous Close: $1.75
  • 50 Day Moving Average: $1.78
  • 200 Day Moving Average: $1.72
  • P/E Ratio: N/A
  • P/E Growth: 0.28
  • Market Cap: $408.31M
  • Current Quarter EPS Consensus Estimate: $-0.34 EPS
Additional Links:
Arena Pharmaceuticals (NASDAQ:ARNA) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha